Fragment-Based Screen of SARS-CoV‑2 Papain-like Protease (PLpro)

• Published in: ACS medicinal chemistry letters Vol. 15; no. 8; pp. 1351 - 1357
• Main Authors: Taylor, Ashley J., Amporndanai, Kangsa, Rietz, Tyson A., Zhao, Bin, Thiruvaipati, Anusha, Wei, Qiangqiang, South, Taylor M., Crow, Mackenzie M., Apakama, Chideraa, Sensintaffar, John L., Phan, Jason, Lee, Taekyu, Fesik, Stephen W.
• Format: Journal Article
• Language: English
• Published: American Chemical Society 08.08.2024
• Subjects: Letter; SARS-CoV-2; fragment-based drug discovery; PLpro; NMR screening; antiviral
• ISSN: 1948-5875; 1948-5875
• DOI: 10.1021/acsmedchemlett.4c00238

Coronaviruses have been responsible for numerous viral outbreaks in the past two decades due to the high transmission rate of this family of viruses. The deadliest outbreak is the recent Covid-19 pandemic, which resulted in over 7 million deaths worldwide. SARS-CoV-2 papain-like protease (PLPro) plays a key role in both viral replication and host immune suppression and is highly conserved across the coronavirus family, making it an ideal drug target. Herein we describe a fragment-based screen against PLPro using protein-observed NMR experiments, identifying 77 hit fragments. Analyses of NMR perturbation patterns and X-ray cocrystallized structures reveal fragments bind to two distinct regions of the protein. Importantly none of the fragments identified belong to the same chemical class as the few reported inhibitors, allowing for the discovery of a novel class of PLPro inhibitors.